EcoDrugPlus

Adrenoceptor Alpha 1aa

Ensembl ID : ENSGACG00000011382
Gene Symbol: ADRA1AA
1 Cross references
202 Possible Orthologues:

Adrenoceptor Alpha 1bb

Ensembl ID : ENSGACG00000018139
Gene Symbol: ADRA1BB
1 Cross references
192 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSGACG00000017994
Gene Symbol: ADRA1D
1 Cross references
195 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSGACG00000018686
Gene Symbol: ADRA2A
1 Cross references
176 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSGACG00000009518
Gene Symbol: ADRA2A
1 Cross references
160 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSGACG00000019417
Gene Symbol: ADRA2C
2 Cross references
156 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSGACG00000018364
Gene Symbol: ADRA2C
1 Cross references
162 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSGACG00000006578
Gene Symbol: ADRB1
1 Cross references
163 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSGACG00000020453
Gene Symbol: ADRB2
1 Cross references
168 Possible Orthologues:

Adrenoceptor Beta 2, Surface A

Ensembl ID : ENSGACG00000018455
Gene Symbol: ADRB2A
1 Cross references
196 Possible Orthologues:

Adrenoceptor Beta 3a

Ensembl ID : ENSGACG00000011022
Gene Symbol: ADRB3A
1 Cross references
197 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 1

Ensembl ID : ENSGACG00000018891
Gene Symbol: AKR1B1.1
1 Cross references
350 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).